condition-guides

Published by Floriva · Updated 2026-04-29 · How Floriva checks its guides

PMDD Treatment Options: What Works, Ranked by Evidence

PMDD treatment options ranked by evidence. SSRIs (strongest), hormonal suppression, aerobic exercise, and dietary interventions. How to approach treatment when diagnosis is confirmed.

PMDD has a clear evidence hierarchy. SSRIs and SNRIs have the strongest evidence and work even in luteal-phase-only dosing because their mechanism in PMDD is faster-acting than conventional antidepressant effects (via allopregnanolone, not just serotonin reuptake). Hormonal suppression (OCP, GnRH agonists) eliminates cycles. Aerobic exercise has RCT evidence with effect sizes comparable to pharmacotherapy for some patients. Dietary changes and supplements are modifiers, not primary treatments. Diagnosis must be confirmed with two prospective cycles of tracking before starting treatment.

PMDD treatment starts with a confirmed diagnosis, and the DSM-5 requires two cycles of prospective tracking to confirm it. If you've done that work and your data shows consistent, severe, cycle-locked symptoms, here's what the evidence supports.

Before Treating: What You Need

A confirmed PMDD diagnosis requires:

• Daily symptom ratings across 2 consecutive cycles

• Evidence that symptoms are substantially absent in the follicular phase (Days 1-10 or so) and present in the luteal phase

• Symptoms severe enough to cause marked functional impairment

• Resolution of symptoms within a few days of menstruation

Starting treatment before confirming the cycle-locked pattern means potentially treating a mood disorder (depression, generalized anxiety, bipolar disorder) with a PMDD-specific approach, which may partially work but not address the underlying condition.

Tier 1: SSRIs and SNRIs. First-Line Treatment

How They Work for PMDD

SSRIs work for PMDD through a different mechanism than they work for depression. That is why two things are true:

1. They work within days of starting luteal-phase dosing (not the 4 to 6 weeks needed for depression).

2. Luteal-phase-only dosing is as effective as continuous dosing.

The mechanism: SSRIs upregulate 3α-hydroxysteroid dehydrogenase (3α-HSD), an enzyme that converts progesterone to allopregnanolone. Higher allopregnanolone levels in the luteal phase normalize GABA-A receptor sensitivity, reducing the dysphoric response to allopregnanolone fluctuations.

Which SSRIs Have Evidence

• Fluoxetine (Prozac): FDA-approved specifically for PMDD under the name Sarafem. Multiple RCTs.

• Sertraline (Zoloft): Multiple RCTs; currently most commonly prescribed for PMDD.

• Citalopram: RCT evidence.

• Paroxetine (Paxil): RCT evidence; more side effects than alternatives.

• Escitalopram: Evidence, though fewer PMDD-specific trials than older agents.

Dosing Approaches

Continuous dosing: Standard antidepressant dosing throughout the full cycle. Effective; may produce more side effects than intermittent dosing.

Luteal-phase dosing: Starting the SSRI on cycle Day 14 (or on confirmed ovulation day) and stopping at the onset of menstruation. This is the evidence-supported intermittent approach. Not effective for concurrent depression; only for PMDD.

Symptom-onset dosing: Starting the SSRI when PMDD symptoms first appear and stopping at menstruation onset. More flexible; requires awareness of symptom patterns.

Practical note: SSRIs for PMDD require a prescription. Bring your cycle tracking data to the appointment. It demonstrates the cycle-locked pattern and supports the diagnosis.

Side Effects

Common SSRI side effects: nausea (usually transient), headache, sexual side effects (decreased libido, anorgasmia), sleep disturbance. Weight gain is less common than often reported for short-term use but a concern for continuous dosing. Discuss with your prescriber.

Tier 2: Hormonal Suppression

Rationale

PMDD is caused by abnormal sensitivity to normal luteal-phase hormonal changes. If the luteal phase is eliminated, PMDD symptoms should be eliminated too. This is the logic behind hormonal suppression.

Combined Oral Contraceptives

The evidence is mixed. Some OCP formulations improve PMDD, others worsen it, and some have no effect. The one OCP with specific RCT evidence for PMDD is drospirenone-containing pills (Yaz, Yasmin, generic equivalents). Drospirenone is a progestin with antiandrogenic and antimineralocorticoid properties that appears to be better tolerated in PMDD patients than other progestins.

Note that some people with PMDD find that OCPs worsen their symptoms, possibly because the synthetic progestin component activates GABA-A receptors differently than natural progesterone. Individual response varies.

GnRH Agonists (Medical Menopause)

GnRH agonists (leuprolide, nafarelin, goserelin) suppress the entire HPG axis, eliminating ovarian estrogen and progesterone production, effectively creating a reversible medical menopause. This is the most effective hormonal intervention for PMDD (near-complete symptom elimination in most patients) and also the most intensive.

Side effects: Hot flashes, night sweats, vaginal dryness, mood changes, and most significantly, bone density loss with long-term use (>6 months). "Add-back" therapy (low-dose estrogen + progesterone) reduces side effects.

GnRH agonists are generally reserved for severe, treatment-refractory PMDD that has not responded to SSRIs and is not manageable with OCPs.

Tier 3: Aerobic Exercise. Evidence-Based and Often Overlooked

Multiple studies have found aerobic exercise significantly reduces PMDD symptom severity. One RCT comparing exercise to a waitlist control found effect sizes comparable to medication. That finding receives far less attention than the SSRI literature.

The protocol: 3-5 aerobic sessions per week, 30-45 minutes each, at moderate-to-vigorous intensity. Importantly, the benefit appears to require consistent exercise throughout the entire cycle, not just in the luteal phase.

Mechanisms: Aerobic exercise increases allopregnanolone levels (same mechanism as SSRIs, upregulating 3α-HSD), reduces cortisol, increases BDNF, and modulates the HPA axis reactivity that amplifies luteal-phase symptoms.

For mild-to-moderate PMDD, regular aerobic exercise is a clinically meaningful treatment. For severe PMDD, it can be used in combination with pharmacotherapy.

Tier 4: Dietary and Supplement Interventions (Modifiers, Not Primary Treatment)

These reduce severity and can meaningfully help at mild-moderate levels, but are typically insufficient as standalone treatments for clinical PMDD.

Alcohol Reduction

Alcohol acutely worsens PMDD. The luteal phase involves heightened HPA reactivity; alcohol (which also activates and then dysregulates GABA-A receptors) amplifies the dysphoric component. Eliminating alcohol during the luteal phase is one of the most impactful non-pharmacological adjustments.

Magnesium

300-360mg elemental magnesium glycinate daily. Multiple RCTs for PMS; the HPA modulation effect is particularly relevant for PMDD's stress-amplification component.

Vitamin B6

50-100mg/day. RCT evidence for PMS mood symptoms; cofactor in serotonin synthesis.

Calcium

600-1200mg daily. Epidemiological association with lower PMS/PMDD severity; some trial evidence. Likely works through vitamin D/parathyroid hormone interaction rather than direct hormone effects.

SSRIs Over Supplements

For confirmed PMDD, supplements can reduce severity but do not address the allopregnanolone sensitivity dysregulation that drives the disorder. If tracking data shows symptoms consistent with PMDD criteria, supplements alone are unlikely to produce adequate relief. There is no reason to avoid effective pharmacotherapy while suffering.

Cognitive Behavioral Therapy (CBT)

Small RCTs support CBT for PMDD, specifically for reducing the functional impairment from symptoms (coping with the symptoms that persist even with pharmacotherapy). CBT is more commonly used as an adjunct to pharmacological treatment than as a primary treatment. The cycle-specific component is cognitive reframing: recognizing that premenstrual mood states are hormonally driven and will resolve, reducing the secondary anxiety of "what's wrong with me" during the luteal phase.

What to Bring to the Appointment

1. Two cycles of daily symptom tracking, severity ratings (1-10) for each core symptom, by cycle day. Show follicular baseline vs. luteal severity.

2. Functional impact data: missed work, cancelled commitments, relationship impacts

3. Symptom timing, when symptoms appear relative to your cycle, when they resolve

4. What you've already tried, including dietary changes, supplements, and their effects

This data makes a PMDD diagnosis more straightforward and allows the prescriber to target treatment more precisely.

What This Means for Floriva Users

The cycle-locked symptom pattern that defines PMDD is only visible in prospective daily data. Two cycles of mood and symptom logging, starting from Day 1 of each period, creates the prospective record the DSM-5 criteria require. If your data shows consistent luteal-phase symptom spikes with follicular recovery, that documentation moves you from "I think I have PMDD" to "my data confirms PMDD."